Calidi (CLDI) Biotherapeutics priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share. The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $4.25 million. Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Calidi announces common stock offering, no amount given
- Calidi files to sell 6.94M shares of common stock for holders
- Calidi Biotherapeutics Reveals Promising Virotherapy Data
- Calidi presents data on RTNova systemic technology in metastatic lung cancer